t
Sareum Holdings PLC announced on 27 March 2025 that Executive Chairman Dr Stephen Parker purchased 84,033 ordinary shares in the Company at an average price of 11.9 pence per share on 26 March 2025. Following this transaction, Dr Parker holds a direct and indirect interest in an aggregate of 405,045 Ordinary Shares, representing approximately 0.30 per cent of Sareum's currently issued share capital.
| Date | 27 Mar 2025 |
| Time | 07:00:15 |
| Category | Director/PDMR dealings |
| ID | 3635C |
Sareum Holdings PLC
("Sareum" or the "Company")
Director's Dealing
Cambridge, UK, 27 March 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that Dr Stephen Parker, Executive Chairman, purchased 84,033 ordinary shares of 1.25 pence each in the capital of the Company ("Ordinary Shares") at an average price of 11.9 pence per share on 26 March 2025.
In addition, persons connected with Dr Parker are interested in a further 25,680 Ordinary Shares in the Company, over which Ordinary Shares Dr Parker has voting rights discretion.
Therefore, following the transaction, Dr Parker has direct and indirect interests in an aggregate 405,045 Ordinary Shares in the Company, representing approximately 0.30 per cent. of the Company's currently issued share capital.
The notification below, which has been made in accordance with the requirements of the Market Abuse Regulation, provides further details.
PDMR Notification Form:
|
1 |
Details of the person discharging managerial responsibilities/person closely associated
|
|||||
|
a) |
Name |
Stephen Parker |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
Executive Chairman |
||||
|
b) |
Initial notification/amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Sareum Holdings plc |
||||
|
b) |
LEI |
213800PKERN2DY8FFM72 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of 1.25 pence each in the share capital of Sareum Holdings plc |
||||
|
|
|
|
||||
|
|
Identification code |
GB00B02RFS12 |
||||
|
|
|
|
||||
|
b) |
Nature of the transaction |
Purchase of shares |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
|
£0.119 |
84,033 |
|
|
|
d) |
Aggregated information |
|
|
|||
|
|
|
|
|
|||
|
|
- Aggregated volume |
84,033 Ordinary Shares |
|
|||
|
|
|
|
|
|||
|
|
- Weighted Average Price |
11.9 pence per Ordinary Share |
|
|||
|
|
|
|
|
|||
|
e) |
Date of the transaction |
26 March 2025 |
|
|||
|
f) |
Place of the transaction |
London Stock Exchange (AIM) |
|
|||
The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014, which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.
- ENDS-
For further information, please contact:
|
Sareum Holdings plc Stephen Parker, Executive Chairman |
01223 497700 |
|
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman
|
020 7409 3494 |
|
Oberon Capital (Joint Broker) Mike Seabrook / Nick Lovering
|
020 3179 5300 |
|
Hybridan LLP (Joint Broker) Claire Noyce
|
020 3764 2341 |
|
ICR Healthcare (Financial PR) Jessica Hodgson / Davide Salvi |
020 3709 5700 |
About Sareum
Sareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with a planned initial focus on psoriasis.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.
The Company has recently acquired the license for SRA737, a clinical-stage Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.
Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com